Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-Intensified Post-operative Chemoradiation for HPV-positive Oropharyngeal Cancer
NCT04502407Phase 2Active, not recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Feb 2021
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132) in human papillomavirus-positive oropharyngeal squamous cell carcinoma, sponsored by Cedars-Sinai Medical Center. Started Feb 2021; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
human papillomavirus-positive oropharyngeal squamous cell carcinoma
Beyond the preview
Go deeper on NCT04502407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502407.